Related Experiment Video

Updated: May 13, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Differential effects of phenethyl isothiocyanate and D,L-sulforaphane on TLR3 signaling

Jianzhong Zhu1, Arundhati Ghosh, Elizabeth M Coyle

  • 1Cancer Virology Program, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|March 20, 2013
PubMed

Insights

Naturally occurring isothiocyanates (ITCs) show distinct effects on Toll-like receptor 3 (TLR3) signaling. Phenethyl isothiocyanate (PEITC) inhibits IRF3 signaling, while sulforaphane (SFN) inhibits NF-κB signaling, impacting cancer cell apoptosis and growth.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • Naturally occurring isothiocyanates (ITCs) from cruciferous vegetables are recognized for their cancer chemopreventive properties.
  • Toll-like receptor 3 (TLR3) plays a crucial role in innate immune responses, particularly against viral infections and in cancer development.

Purpose of the Study:

  • To investigate the differential effects of two prominent ITCs, phenethyl isothiocyanate (PEITC) and D,L-sulforaphane (SFN), on TLR3-mediated signaling pathways.
  • To elucidate the mechanistic differences between PEITC and SFN in modulating TLR3 signaling.
  • To assess the biological significance of these differential effects on antitumor activities.

Main Methods:

  • In vitro and in vivo studies examining TLR3 signaling pathways, including IRF3 and NF-κB activation.
  • Analysis of TLR3 ligand-dependent dimerization.
  • Assays evaluating dsRNA-mediated apoptosis of tumor cells and anchorage-independent growth of immortalized fibroblasts.

Main Results:

  • PEITC selectively inhibited TLR3-mediated IRF3 signaling and downstream gene expression by preventing TLR3 dimerization.
  • SFN inhibited TLR3-mediated NF-κB signaling without disrupting TLR3 dimerization, affecting downstream pathways.
  • PEITC antagonized dsRNA-induced tumor cell apoptosis and colony formation inhibition, whereas SFN augmented these responses.

Conclusions:

  • PEITC and SFN exhibit distinct mechanisms in modulating TLR3 signaling, leading to differential effects on innate immunity and antitumor activities.
  • These findings highlight functionally relevant differences between structurally similar ITCs.
  • The study provides insights for targeted therapeutic development of ITCs in cancer treatment.

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...